A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

QLT Inc.0 sites490 target enrollmentJune 2002

ConditionsStage IIIb Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer

Drugstariquidar + vinorelbine placebo + vinorelbine

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Stage IIIb Non-small Cell Lung Cancer
Sponsor: QLT Inc.
Enrollment: 490
Status: Terminated
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

To determine whether tariquidar + first-line single agent vinorelbine chemotherapy in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + vinorelbine. To compare the effects of tariquidar/vinorelbine with placebo/vinorelbine on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.

Registry

clinicaltrials.gov

Start Date

June 2002

End Date

June 2003

Last Updated

13 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

QLT Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients who have histologically or cytologically proven NSCLC, stage IIIb or stage IV, requiring first-line chemotherapy.
•Patients who have a WHO performance status of 2 and life expectancy of greater than 3 months.
•Patients who are 18 years of age or older and age of consent.
•Patients who are women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test (serum or urine) at screening, and must be practicing an adequate method of birth control.
•Patients who have neutrophils greater or equal to 1.5 x 103/µL; platelets greater or equal to 100 x 103/µL; bilirubin less or equal to 1.5 times the upper limit of normal or less or equal to 26 µmol/L (1.5 mg/dL); transaminases less or equal to 2.5 times the upper limit of normal or, for patients with known liver metastases, less or equal to 5 times the upper limit of normal; and creatinine equal or less than 141 µmol/L (1.6 mg/dL) or calculated creatinine clearance less or equal to 60 mL/min prior to study treatment.
•Patients who are able to give written informed consent and comply with the protocol.

Exclusion Criteria

•Patients who are eligible for radiotherapy or surgery for curative intent.
•Patients who have had previous chemotherapy for NSCLC.
•Patients who have a WHO performance status less than 2 or greater than
•Patients with bronchoalveolar carcinoma (an adenocarcinoma in which cylindrical tumor cells grow upon the walls of pre-existing alveoli, from WHO histological typing of lung tumors \[66\]).
•Patients who have previous or current primary malignancies at other sites within the last 5 years, with the exception of adequately treated cone-biopsied carcinoma of the cervix and basal or squamous cell skin carcinoma.
•Patients who are a poor medical risk because of other nonmalignant systemic diseases or active uncontrolled infections.
•Patients who have symptomatic brain metastases.
•Patients who have other medical or surgical conditions that would contraindicate chemotherapy.
•Patients who have received experimental therapies within the last 4 weeks.
•Patients who have know hypervitaminosis or known sensitivity to ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, d-panthenol, or vitamin E.